
Equillium Inc (EQ) Stock Forecast & Price Target
Equillium Inc (EQ) Analyst Ratings
Bulls say
Equillium Inc. is positioned positively due to the promising efficacy of its lead candidate, EQ504, showing notable immunomodulatory effects in patients with ulcerative colitis, including multiple patients achieving clinical remission. The observed improvement in liver function tests and significant reductions in endoscopic scores support the potential for EQ504 to succeed in clinical applications, further enhancing confidence in its development. With the projected timeline for Phase 1 initiation set for mid-2026, the robust early data suggests substantial value creation opportunities for the company as it advances its therapeutic pipeline.
Bears say
Equillium Inc. faces significant challenges that contribute to a negative outlook on its stock, primarily due to the uncertain clinical trajectory of its lead product, EQ504. Potential competitive threats from developments like Azora’s AT-177 and concerns about safety signals or negative Phase 1 data could diminish EQ504's market positioning and overall value, potentially leading to substantial declines in stock price. Furthermore, failure to secure favorable financing for Phase 2a trials or adverse developments related to the AhR therapeutic index could result in dilutive financing at unfavorable terms, exacerbating financial vulnerabilities.
This aggregate rating is based on analysts' research of Equillium Inc and is not a guaranteed prediction by Public.com or investment advice.
Equillium Inc (EQ) Analyst Forecast & Price Prediction
Start investing in Equillium Inc (EQ)
Order type
Buy in
Order amount
Est. shares
0 shares